BIO breaks a falling wedge with confirmed volume, pulling back to Fibonacci support before a potential $0.0482 retest.

Bio-Rad Laboratories' investment returns are expected to be hindered by economic and technical factors. The company's large ownership in Sartorius AG has been a hindrance due to the latter's poor ...

Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.

Two leaders on the House’s Select Committee on the CCP last week requested an intelligence briefing on the CDMO GenScript and its three related businesses over suspicions that the firms are linked to ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.